Impact of age and comorbidity on survival in XXXX .

@entity1 @entity5 @entity694 @entity14 @entity204
BACKGROUND: @entity1 with @entity14 are often excluded from clinical trials based on age or a poor performance score. However, 70% of @entity14 is diagnosed in @entity1 over 65. Evaluation on the influence of age and comorbidity on survival and cause of @entity204 in a non-selected population. METHODS: Included were 621 consecutive @entity1 with @entity14 . An extensive chart review was performed for 392 @entity1 with @entity694 and 143 @entity1 with @entity5 . Analyses were performed separately for both groups. RESULTS: Median survival of @entity694 @entity1 was 5.13 years, 131 @entity1 (34.3%) died from @entity5 progression. Age and comorbidity were significant predictors for overall survival (P<0.001). Age was also a significant predictor of cause of @entity204 (P=0.001). In @entity5 @entity1 median survival was 4.67 years, 51 (35.7%) of @entity1 died from @entity5 progression. Neither age nor comorbidity was significant predictors of survival. Age was a significant predictor of cause of @entity204 (P<0.001). CONCLUSIONS: In @entity694 @entity1 age and comorbidity predict survival. This represents possible bias or a reduced survival benefit of treatment, and is an indication that @entity694 is not the prognosis defining illness in the majority of @entity1 . In @entity5 @entity1 neither age or comorbidity significantly impacted survival.
